: iStockAnalyst.com Symbols Feed

Tech Talk From McMillan

Thu, 03 Dec 2009 14:45:07 GMT

"Nothing has changed to unseat this liquidity-driven rally," says options expert Larry McMillan. In The Daily Strategist, he eyes the technical side of the market and some new trading ideas.[More...]

Invest In HealthCare!

Tue, 01 Dec 2009 16:52:08 GMT

In 3 of the past 4 market rebounds since 1982, equity gains slowed to a single digit pace in the 2nd year, after the initial rally. Now dividend stocks have extra appeal because they offer a tempting alternative to CDs which pay virtually no interest at all, and long term bonds which pay a little bit more but leave you at the mercy of inflation. Established value companies in stable industries have usually proven a better long-term investment. Before S&P cut Pfizer (PFE) ratings to 'AA' from 'AAA' on Oct 16, 2009, there were 5 companies with AAA credit ratings: Automated Data Processing (ADP), Johnson & Johnson (JNJ), ExxonMobil (XOM) and Microsoft (MSFT). In other words, 2 out of 5 were healthcare companies.[More...]

Technical Breakout Alert Issued For CytRx (NASDAQ:CYTR)

Mon, 23 Nov 2009 13:57:08 GMT

Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/23/09 on CytRx Corporation (NASDAQ:CYTR). Shares of the company finished trading during 11/20/09 at $1.35 per share, up 20.18% from the opening bell on heavy buying pressure. As of 11/18/09, the biopharmaceutical company announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.[More...]

Blue-Chip Biotechs Maneuver To Collect Monopoly Profits: AMGN, BIIB, GENZ

Fri, 20 Nov 2009 19:06:25 GMT

By Dr. George Huang It's hard to find winners in the nightmarish health care reform bill passed by the House... The bill doesn't address the major complaint of the American consumers – soaring costs. In fact, health insurers already predict skyrocketing premiums next year. Instead, the bill forces most employers to provide health care coverage or pay a tax penalty of up to 8% of payroll. The added cost will crush many small businesses.[More...]

Options Intelligence Report : Options Activity Analysis For XRX, SLE, AMGN, ESI, EBAY, FFIV, SLE

Thu, 22 Oct 2009 18:14:46 GMT

Today's tickers: XRX, SLE, AMGN, ESI, EBAY, FFIV & SLE[More...]

Get Instant Biotech Diversification

Thu, 22 Oct 2009 17:04:36 GMT

Biotechnology is a notoriously volatile industry. Shares of individual firms often skyrocket or plummet based on clinical test results. Because biotechs tend to march to the beat of their own drum--share prices are much more sensitive to clinical trial results and merger activity within the sector than they are to the economic backdrop—they can be an interesting small addition to a satellite portfolio.[More...]

Monday Morning Musings: Oct 19, 2009

Mon, 19 Oct 2009 15:59:39 GMT

The market is bouncing higher this morning after Friday's lackluster session. The S&P 500 is actually right back at its highs for the year, with broad participation among the various sectors.[More...]

This Fall Will Be Crazy For These Biotech Stocks

Fri, 16 Oct 2009 18:50:27 GMT

Most speculators have it all wrong when it comes to biotech trading... They'll buy biotech stocks ahead of FDA decisions, hoping an approval will bring 100% overnight gains. But more often than not, the market is one step ahead. The stock price will creep up as everyone anticipates good news.[More...]

Pressure BioSciences (NASDAQ: PBIO): A New Paradigm For Sample Processing

Mon, 21 Sep 2009 03:49:21 GMT

Pressure BioSciences (NASDAQ: PBIO) is a life science research tools company that is commercializing and developing its innovative core technology platform known as pressure cycling technology (PCT). PCT uses cycles of hydrostatic (water-based) pressure between ambient and ultra-high levels (up to 45,000 PSI) at controlled temperatures to rapidly and repeatedly control interactions at the molecular level.[More...]

Tickers For The Latest Portfolio Reshaping

Fri, 04 Sep 2009 15:45:21 GMT

Fortunately my portfolio management methods don’t revolve around frequent trading. One of my kids came up to me recently and said, “What did you do today, Dad?” I said, “I made one trade, and I did a bunch of research.” He then asked, “How often do you trade?” I answered, “That was my first trade in a week, and I haven’t traded much in the last two months, but that’s not normal. There is no normal for me. When the market is really volatile, I trade a lot more, selling when stocks are rising, and buying when they are selling off. When the market is relatively placid, I don’t do much.” He looked at me, kind of smiled, and moved on. Information overload from Dad. Most people and investment managers trade too often. They sell their winners too rapidly, and panic too soon on their losers. Now, I’m not advocating “buy and forget,” or Buffett’s statement, “Our favorite holding period is forever.”[More...]

China's eager to harness the sun

Tue, 17 Nov 2009 09:51:00 GMT

ANAHEIM, Calif. -- The world's solar companies gathered here recently amid the nation's largest solar market under a brilliant sun -- and the looming shadow of China.
But China is setting itself up to do more than just manufacture components for renewable energy, such as wind and solar.
The buildup of a huge market in China for renewable energy is luring global manufacturers and research teams to China, energy executives say.

: iStockAnalyst.com Symbols Feed

Tech Talk From McMillan

Invest In HealthCare!

Technical Breakout Alert Issued For CytRx (NASDAQ:CYTR)

Blue-Chip Biotechs Maneuver To Collect Monopoly Profits: AMGN, BIIB, GENZ

Options Intelligence Report : Options Activity Analysis For XRX, SLE, AMGN, ESI, EBAY, FFIV, SLE

Get Instant Biotech Diversification

Monday Morning Musings: Oct 19, 2009

This Fall Will Be Crazy For These Biotech Stocks

Pressure BioSciences (NASDAQ: PBIO): A New Paradigm For Sample Processing

Tickers For The Latest Portfolio Reshaping

China's eager to harness the sun

State AGs suing U.S. drug maker Amgen

Business Highlights

The Business Diary

Stock Market, Economy Heading Back to 'Normal'

Stock Market, Economy Heading Back to 'Normal'

Consultant Delivers Report on R.I. Economy

Partial approval for Amgen bone drug

Business Highlights

Business Highlights

Cytokinetics Announces Addition to Board of Directors

NPS Pharmaceuticals Reports Third Quarter Results and Improved Cash Burn Guidance

SaaS Leader Daptiv Adds Amdocs and Microsoft Veteran Chase Franklin As CEO

GENova Biotherapeutics (GVBP) SqueezeTrigger Price is $0.43. Approximately 57 Million Shares Shorted Since July 2009 According to Buyins.Net Research Report

Symyx Joins SAFE-BioPharma to Ensure Safe Security Standards for ELN Software; Pharmaceutical Industry Non-Profit Maintains Standards and Certification for Digital Signatures

Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes

Fusing Science and Society: Media Entrepreneur Adam Bly Launches National Biotechnology Week in London, Ontario

BenchmarkJournal.Com Free Analyst Review for HCBK, PLCE, GNTX, AMGN, NPBC and LAMR

Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer

Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting

Form 4 AMGEN INC For: Nov 23 Filed by: BONANNI FABRIZIO (10K)

Form 4 AMGEN INC For: Nov 18 Filed by: de Carbonnel Francois (10K)

Form 4 AMGEN INC For: Nov 17 Filed by: MCNAMEE BRIAN M (10K)

Form 4 RICHO ANNA For: Nov 05 (10K)

Form 4 BONANNI FABRIZIO For: Nov 05 (10K)

Form 4 SHARER KEVIN W For: Nov 05 (10K)

Form 4 OMENN GILBERT S For: Sep 28 (10K)

Form 3 HENDERSON REBECCA M For: Jul 09 (10K)

Form 4 AMGEN INC For: Jun 09 Filed by: MORROW GEORGE J (10K)

Form 4 BEIER DAVID W For: Jun 03 (10K)